Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial

doi:10.3748/wjg.v25.i46.6790

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 46

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8703)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

568

WORD

403

HTML

4482

Figures (1-1)

349

Tables (1-3)

254

Sum=6056

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

904

Download

1743

Sum=2647

Dec 14, 2019 (publication date) through Dec 24, 2024

Times Cited of This Article

Times Cited (26)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Gastroenterol. Dec 14, 2019; 25(46): 6790-6798
Published online Dec 14, 2019. doi: 10.3748/wjg.v25.i46.6790

Open in New Tab Full Size Figure Download Figure

Figure 1 Study flow chart. mBCQT: Modified bismuth-containing quadruple therapy; CT: Concomitant therapy; ITT: Intention-to-treat; PP: Per-protocol.

Citation: Kim SJ, Chung JW, Woo HS, Kim SY, Kim JH, Kim YJ, Kim KO, Kwon KA, Park DK. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial. World J Gastroenterol 2019; 25(46): 6790-6798
URL: https://www.wjgnet.com/1007-9327/full/v25/i46/6790.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i46.6790